Syn2bio S.A.
Company Overview
Syn2bio S.A. is a Polish radiopharmaceutical company created through the demerger of Synektik S.A. The company focuses on the SYN2 cardiotracer, an innovative radiopharmaceutical for myocardial perfusion testing and diagnosis of coronary artery disease, and on further development of new pharmaceutical compounds.
Business Segments
- SYN2 Cardiotracer – innovative radiopharmaceutical for diagnosis of coronary artery disease
- Licensing and Partnering – commercialization through partners in Europe, North America, and selected Asian markets
- Recurring Consumables – disposable synthesis cassettes and chemical precursor for SYN2 production
Key Drivers
- Positive completion of phase-three clinical trials for SYN2
- Regulatory approval by FDA and EMA
- Signing licensing or partnering agreements with global pharmaceutical or radiopharmaceutical companies
- Expansion and maintenance of patent protection in key markets
- Future development of additional radiopharmaceutical projects in nuclear medicine
Key Risks
- Failure or delay of phase-three clinical trials
- Regulatory rejection or delays by FDA or EMA
- Inability to secure attractive commercialization partners
- Patent protection challenges or weaker-than-expected IP position
- Dependence on a single flagship product before broader pipeline development
What to Watch
- Phase-three clinical trial progress and final results
- FDA and EMA registration pathway updates
- Licensing, sublicensing, or partnering agreements
- Patent approvals and IP protection in the United States, Europe, Japan, and other markets
- Commercial model for SYN2 cassettes and chemical precursor sales
Foundational Analysis
Business Model
Syn2bio intends to monetize SYN2 primarily through a licensing and partnering model, using partners with radiopharmaceutical production, regulatory, logistical, and commercial infrastructure. The company also plans to retain rights to design and distribute disposable SYN2 synthesis cassettes and sell the chemical precursor required for production.
Competitive Positioning
Syn2bio’s positioning depends mainly on the clinical, regulatory, and patent strength of SYN2. If phase-three trials and registration are successful, the company could offer a differentiated cardiotracer for myocardial perfusion diagnostics, but it remains highly dependent on product validation and partner execution.
Economics & Capital Allocation
Syn2bio is an early-stage radiopharmaceutical commercialization company rather than a mature revenue-generating operating business. The intended model is capital-light relative to building a global sales and manufacturing network directly, but near-term economics are dominated by R&D, clinical, regulatory, patent, and commercialization costs.
Capital allocation is expected to focus on completing SYN2 development, regulatory preparation, patent protection, partner negotiations, and future nuclear medicine R&D projects. Public financial history is limited because Syn2bio is a newly separated company.
Long-term Risks
The main long-term risks are clinical failure, regulatory rejection, lack of commercial partners, weaker-than-expected adoption by nuclear medicine providers, patent challenges, and concentration on one flagship asset.
What Would Break the Thesis
- Negative or inconclusive phase-three clinical trial results
- FDA or EMA rejection or materially delayed approval process
- Failure to sign a credible global or regional commercialization partner
- Loss of key patent protection or inability to secure US patent protection
- Evidence that SYN2 has limited clinical or economic advantage versus existing diagnostic alternatives
Contracts Intelligence
No contract data available for this company.
View News InsteadFinancial Performance
No financial data available for this company.
Please try again later or contact support if the issue persists.
Recent News & Developments
Sentiment Analysis (Last 6 Months)
| Positive | 50% |
| Neutral | 50% |
| Negative | 0% |
Based on 4 articles
Syn2Bio S.A. Board Member's Close Associate Acquires Company Shares
On April 20, 2026, Syn2Bio S.A. announced a transaction involving the acquisition of 2,300 company shares by Mr. Maciej Zarębiński, a close associate of Ms. Sawa Zarębińska, a member of the Supervisory Board. The shares were purchased at a price of 34 PLN per share on April 16, 2026, through the Warsaw Stock Exchange (XWAR). The transaction was disclosed in compliance with Article 19(1) of the MAR Regulation, and the full notification is available in the company's official report.
This development highlights the confidence of individuals closely associated with Syn2Bio's leadership in the company's future prospects, particularly as it advances its innovative cardiotracer radiopharmaceutical through phase-three clinical trials and continues its efforts in pharmaceutical research and commercialization.
Insider Transaction Reported at Syn2Bio S.A. Involving Board Member's Close Associate
On April 20, 2026, Syn2Bio S.A. announced a transaction involving the acquisition of company shares by Ms. Zuzanna Zarębińska, a close associate of Ms. Sawa Zarębińska, a member of the Supervisory Board. The transaction, conducted on April 16, 2026, involved the purchase of 30 shares at a price of 33.9 PLN per share on the Warsaw Stock Exchange (XWAR). The notification was made in compliance with Article 19(1) of the MAR Regulation, and the full details are available in the attached report.
This development highlights the ongoing confidence in Syn2Bio S.A.'s strategic direction and its innovative projects, including the advanced phase-three clinical trials of its cardiotracer radiopharmaceutical for heart disease diagnosis.
Syn2Bio S.A. Acquires Founding Shares for Strategic Realignment
On April 22, 2026, Syn2Bio S.A., headquartered in Warsaw, finalized an agreement to acquire 200,000 Series A bearer shares, representing 2.29% of its share capital. The shares, valued at a nominal price of 0.50 PLN each, were purchased for a total of 100,000 PLN from shareholders Anna Szymańska and Cezary Kozanecki. This acquisition follows a preliminary agreement signed on February 18, 2026, and detailed in the company's prospectus approved by the Polish Financial Supervision Authority on March 12, 2026.
The acquired shares, originally technical founding shares, were issued to facilitate the division of Synektik S.A. and align the shareholder structure of Syn2Bio S.A. with that of Synektik S.A. The company plans to cancel these shares during the next general shareholders' meeting, ensuring a streamlined ownership structure.
Relevance: This strategic move underscores Syn2Bio S.A.'s commitment to optimizing its corporate structure as it advances its flagship cardiotracer radiopharmaceutical project, currently in phase-three clinical trials.
Syn2Bio S.A. Announces Extraordinary General Meeting to Address Key Corporate Decisions
Syn2Bio S.A., a leading Polish company specializing in innovative radiopharmaceuticals for heart disease diagnosis, has announced the convening of an Extraordinary General Meeting (EGM) scheduled for May 19, 2026, at its headquarters in Warsaw. The meeting will address critical corporate matters, including the voluntary redemption of 200,000 company shares, a reduction in share capital, and amendments to the company's statute. Additionally, the agenda includes the adoption of a new remuneration policy and the approval of the updated regulations for the Supervisory Board.
The share capital reduction aims to align the company's capital structure with its post-reorganization shareholder composition following the division of Synektik S.A. The new remuneration policy seeks to enhance corporate governance and align executive compensation with long-term business goals. The meeting will also finalize the rules governing the Supervisory Board, ensuring compliance with corporate governance standards.
Relevance to Syn2Bio S.A.: These decisions are pivotal for Syn2Bio S.A. as they directly impact its organizational structure and governance, which are crucial for the successful commercialization of its cardiotracer project currently in Phase III clinical trials.
2026 EPS Estimates
- Clinical trial delay or failure, regulatory setback, weak partner interest, patent challenges, or higher-than-expected financing needs before commercialization
- No reliable public EPS estimate included
- Base case depends on successful phase-three completion, regulatory pathway progress, and at least one credible licensing or partnering agreement
- Positive phase-three results, favorable FDA and EMA registration process, attractive global licensing terms, and recurring revenue from SYN2 cassettes and chemical precursor sales
Note: EPS estimates are for informational purposes only and represent our analytical framework, not investment recommendations. These financial results estimates are based on stated assumptions and may change as new information becomes available.
Key Metrics
Company-specific performance indicators tailored to Syn2bio S.A.'s business model.
No key metrics available yet
Custom performance indicators for Syn2bio S.A. will appear here once available.
Examples of metrics we track:
Data Source: Key metrics are extracted from company disclosures, periodic reports, and management commentary.
Periodic Report Publication Calendar
No report publication schedule available yet for this company.